靶向HP-PRRSV ORF7基因的siRNA重组伪狂病病毒的体外复制抑制效果

为了评价靶向高致病性猪繁殖与呼吸综合征病毒(HP-PRRSV)ORF7的siRNA重组伪狂犬病病毒(rPRV)对HP-PRRSV复制的体外抑制效果。将500MOI的siRNA rPRV:rPRV gG-/siRNA N1、rPRV gG-/siRNA N2、rPRV gG-/siRNA N3分别感染Marc-145细胞,24h后再分别接种10 MOI PRRSV,感染病毒48h后,观察其抑制HPPRRSV HN1株复制效果;待细胞感染病毒72h后,应用间接免疫荧光试验(IFA)、实时荧光定量PCR及Western blot检测重组rPRV介导的siRNA对HP-PRRSV在细胞中复制的抑制作用。结果显示,与表达突变siRNA的rPRV gG-/siRNA Neg及接毒对照组相比,HP-PRRSV在细胞中的复制均可被3个siRNA rPRV有效抑制,其中重组病毒rPRV gG-/siRNA N2抑制效果最佳;进一步检测siRNA重组rPRV在Marc-145细胞中抑制HP-PRRSV HN1株的复制效果,结果显示,与对照组相比,重组病毒rPRV gG-/siRNA N1和rPRV gG-/siRNA N3抑制作用不明显,而rPRV gG-/siRNA N2不但能够有效抑制HP-PRRSV引起的细胞病变,而且能够消减HP-PRRSV N蛋白的表达,明显降低ORF7mRNA的表达水平(P0.05),且其抑制作用具有剂量依赖性,其抑制效果至少可持续5d,但随着时间的延长逐渐减弱。结果提示siRNA rPRV在体外能抑制HP-PRRSV的复制。     

伪狂犬病病毒gE/TK基因缺失突变株的构建

在伪狂犬病病毒转移载体pBdTK-Uni的多克隆位点中插入由SV40启动子控制下的IacZ基因表达盒,同时在右侧同源臂下游插入一个1.7kb的KpnI片段,构建成一个新的转移载体pUhi-LacZ.用该载体与Bartha-K61株基因组通过脂质体法共转染Vero细胞,经过10代蓝斑筛选纯化和PCR鉴定获得了一株稳定表达LacZ基因的伪狂犬病病毒gE/TK基因缺失突变株,命名为rPrV-LacZ.在不同的细胞(PK-15、IBRS-2、Vero和CEF)上,对该重组病毒与亲本病毒的增殖滴度和细胞病变进行比较,未见显著差异.结果表明转移载体pBdTK-Uni具有实用性,可用于构建伪狂犬病病毒基因工程活载体疫苗.     

表达高致病性猪蓝耳病病毒GP5重组伪狂犬病病毒的构建及鉴定

将PCR扩增的高致病性猪蓝耳病病毒(HP-PRRSV)HuN4株GP5基因与含绿色荧光蛋白(EGFP)基因的表达盒插入到伪狂犬病毒通用转移载体pgG-uni中,构建了转移载体pgG-HPGP5-EGFP.通过磷酸钙法将转移载体pgG-HPGP5-EGFP和PRV Bartha-K61株的基因组共转染Vero细胞,经过8轮荧光蚀斑筛选和PCR鉴定获得了稳定表达EGFP的重组病毒,命名为rPRV-HPGP5.WA和western blot结果证实HP-PRRSV HuN4株GP5在重组病毒中得到了有效表达.该重组病毒的获得为高致病性猪蓝耳病基因工程疫苗的研究奠定了基础.     

表达H3N2亚型猪流感病毒HA基因重组伪狂犬病病毒的构建

将SV40启动子控制下的LacZ基因表达盒和CMV启动子控制下的H3N2亚型猪流感病毒（SIV H3N2）的HA基因插入到伪狂犬病病毒（PRV）通用转移载体pBdTK-Uni中，获得转移载体pLTK-HA。将该载体与PRV Bartha-K61株基因组DNA通过脂质体法共转染Vero细胞，经过10代蓝斑筛选、纯化和PCR鉴定获得了一株插入SIV HA基因的重组伪狂犬病病毒，命名为rPRV-HA。Western blotting和间接免疫荧光试验证实HA基因在重组病毒感染的细胞中获得了表达。用不同的细胞（PK-15、IBRS-2、Vero和鸡胚成纤维细胞）对该重组病毒与亲本病毒的增殖滴度和致细胞病变进行比较，未见显著差异，对第30代重组病毒的HA基因进行序列分析，表明该重组病毒遗传性状稳定。     

以伪狂犬病病毒(Bartha-K61)为载体正向表达狂犬病病毒(8202株)糖蛋白重组疫苗的构建

构建以伪狂犬病病毒Bartha-K61株为载体的正向表达狂犬病病毒(8202株)糖蛋白的重组活载体疫苗.将eGFP-rgp的表达框克隆入p8-AA载体的Mlu Ⅰ/Nde Ⅰ酶切位点处,经酶切鉴定为正向连接,阳性重组子命名为p8AA-eGFP/rgp.在质脂体介导下将该质粒与Bartha-K61共转染PK-15细胞,获得rPRV/eGFP/rgp重组病毒.对纯化后的重组病毒进行RT-PCR、Western-blot和间接免疫荧光鉴定.结果表明,重组病毒的滴度(TCID_(50))为10~(8.125)/mL;外源基因在细胞内得到了有效的表达,并具有良好的免疫反应性和遗传稳定性;通过构建表达狂犬病病毒糖蛋白正向重组Bartha-K61的活载体疫苗的研制,为狂犬病疫苗的研制与开发奠定基础.     

表达高致病性猪繁殖与呼吸综合征病毒GP5蛋白的伪狂犬病病毒拯救与纯化

为研制预防高致病性猪繁殖与呼吸综合征病毒(HP-PRRSV)感染的重组伪狂犬病病毒(PRV)活载体疫苗候选毒株，本研究依据HP-PRRSV HuN4毒株GP5基因序列设计并合成1对特异引物，BamHⅠ引入到引物的5′端，从HP-PRRSV毒株的RNA中，用RT-PCR扩增HP-PRRSV GP5基因。将BamHⅠ酶切的PCR产物与同样酶切并去磷酸化的PRV转移载体pG相连接，构建重组质粒pG-GP5/HP-EGFP。采用脂质体转染法将pG-GP5/HP-EGFP质粒转染已接种PRV三基因缺失毒株rPRV-gE^-/gI^-/TK^-的ST细胞中，经病毒空斑纯化，获得携有HP-PRRSV GP5基因和增强型绿色荧光蛋白(EGFP)标记基因的重组伪狂犬病病毒rPRV-GP5/HP-EGFP。将重组病毒rPRV-GP5/HP-EGFP接种CRISPR/Cas9 EGFP敲除质粒转染过的ST细胞，经4轮病毒空斑纯化，最终获得无绿色荧光蛋白的重组病毒rPRV-GP5/HP。经PCR鉴定及测序，证实获得的rPRV-GP5/HP在EGFP基...     

表达口蹄疫病毒P1基因的重组伪狂犬病病毒TK/gG-/PgG-P1的构建

为了构建口蹄疫与伪狂犬病二价基因工程疫苗株 ,将口蹄疫病毒 (FMDV) P1基因插入到伪狂犬病病毒 (PRV)通用载体 p Pg G- uni中 ,得到 PRV转移载体 p Pg G- P1。将转移载体与 Eco R 线性化后的 PRV弱毒疫苗株 TK- /g G- / lac Z 基因组 DNA共转染 PK- 15细胞 ,转染产物经多次空斑纯化和 PCR鉴定 ,获得了纯化的重组 PRV TK- /g G- / Pg G- P1,重组病毒基因组 DNA经酶切鉴定进一步表明 ,FMDV的 P1基因已成功地整合到 PRV弱毒疫苗株的基因组中。Western blot试验表明 ,FMDV P1基因在重组 PRV中得到表达。该研究为进一步研制口蹄疫与伪狂犬病二价基因工程疫苗奠定了坚实的基础     

靶向HP-PRRSV ORF7基因siRNA体外抑制HP-PRRSV HN1株复制研究

为了体外评价靶向高致病性猪繁殖与呼吸综合征病毒(HP-PRRSV) ORF7的siRNA对HP-PRRSV复制的抑制效果。将3μg siRNA重组质粒载体pSilencer-N2转染于Marc-145细胞中,24 h后再分别接种0. 01 MOI PRRSV,感染病毒48 h后,观察其抑制HP-PRRSV HN1株复制效果;待细胞感染病毒72 h后,应用间接免疫荧光试验(IFA)、实时荧光定量PCR及Western Blot检测siRNA重组质粒对HP-PRRSV在细胞中复制的抑制作用。体外结果显示,在最佳接毒量0. 01 MOI和最佳接毒时间24 h时,siRNA重组表达质粒在HP-PRRSV感染后48 h能明显抑制病毒的复制,与对照组相比,病毒滴度降低了2个多数量级,抑制达到100～1 000倍。有效干扰持续时间,检测结果表明,与对照组相比,siRNA重组质粒显著抑制HP-PRRSV的增殖,推迟CPE的发生时间,其抑制作用可以持续到感染后的4天。为高致病性猪繁殖与呼吸综合征防控提供有力的物质支持。     

伪狂犬病病毒TKˉ/gIˉ株PK基因转移载体的构建及LacZ基因表达

伪狂犬病病毒TKˉ/gIˉ株基因组经AscⅠ酶切获得含PK基因的8.7kb片段,将此片段克隆入pPolyⅡ载体的AscⅠ位点,获得中间载体P8-AA,将LacZ表达盒插入其SphⅠ/NdeⅠ位点,构建重组转移载体P8AA-lacZ,将其与伪狂犬病病毒TKˉ/gIˉ株基因组共转染PK-15细胞,细胞出现病变后通过覆盖含有X-gal的营养琼脂进行蓝白斑筛选,通过蚀斑克隆方法分离到重组体PRV（rPRV）,且经过连续传代的rPRV仍能稳定的表达β-半乳糖苷酶活性。通过对重组病毒PRV-LacZ和亲本株TKˉ/gIˉ株TCID50的试验表明,PK基因的缺失对病毒增殖无影响。     

伪狂犬病病毒Bartha株gC膜外区部分基因的原核表达及纯化

构建伪狂犬病病毒(PRV)gC膜外区部分基因的重组质粒,原核表达并纯化目的蛋白.根据GenBank已发表的伪狂犬病病毒Bartha(PRV Ba)株gC基因的序列(NC EU719641),设计并合成了1对引物,以PRV Ba株为模板,PCR扩增出PRV gC膜外区部分基因片段;将该基因片段克隆到原核表达载体pET-28a上,转化大肠埃希菌BL21(DE3),经IPTG诱导,获得大小为35 ku的重组蛋白,命名为pET-gCN813.按照His-Bind纯化试剂盒说明书纯化表达产物,获得融合蛋白的纯化产物.     

Response of cattle persistently infected with bovine virus diarrhoea virus to bovine leukosis virus

Six cattle persistently infected with bovine virus diarrhoea virus (BVDV) and seronegative, and two control, virus negative seropositive cattle were inoculated with lymphocytes infected with bovine leukosis virus (BLV). The two controls produced a normal immune response to BLV, developing antibodies at four and five weeks after inoculation. Two of the six cattle persistently infected with BVDV developed a strong antibody response by six weeks after inoculation with BLV. Four developed a depressed response to BLV, characterised in three by a 'hooking' reaction in the immunodiffusion test which persisted in successive bleedings but was interspersed occasionally by a weak positive reaction. In one of these animals, a series of 'hooking' reactions was followed by a number of negative results. The fourth animal remained serologically negative until 16 weeks after inoculation when a 'hooking' reaction was observed followed by a series of negative results. BLV was isolated from all the cattle persistently infected with BVDV at 42 or 58 weeks after inoculation regardless of whether the serum samples gave negative, 'hooking', weak positive or positive reactions in the immunodiffusion test. BLV was consistently isolated from the nasal secretions of a steer which was BVDV negative but seropositive. The possibility of decreased immune responsiveness to BLV in animals persistently infected with BVDV should be considered when formulating regulations governing the testing of animals for freedom from BLV.     

Feline leukemia virus and feline immunodeficiency virus.

Ophthalmic manifestations of FeLV or FIV infection can occur in all ocular tissues and may be manifestations of direct viral effects or secondary to viral-related malignant transformation. Additionally, the manifestations of common feline ophthalmic pathogens may be more severe and poorly responsive to therapy because of the immunosuppressive effects of FeLV or FIV infection. Prompt diagnosis of underlying viral infection in cats with ophthalmic disease is paramount for accurate diagnosis and prognosis and is required for appropriate therapeutic decision making.     

Evaluating the protective efficacy of a trivalent vaccine containing Akabane virus,Aino virus and Chuzan virus against Schmallenberg virus infection

Schmallenberg virus (SBV), an arthropod borne pathogen, spread rapidly throughout the majority of Europe since 2011. It can cause a febrile disease, milk drop, diarrhea, and fetal malformation in ruminants. SBV, a member of the Simbu serogroup within the genus Orthobunyavirus, is closely related to Akabane virus (AKAV) and Aino virus (AINOV) among others. In the present study, 4 Holstein-Friesian calves were immunized twice four weeks apart with a multivalent, inactivated vaccine against AKAV and AINOV. Another 4 calves were kept as unvaccinated controls. All animals were clinically, serologically and virologically examined before and after challenge infection with SBV. AKAV- and AINOV-specific neutralizing antibodies were detected one week before challenge infection, while SBV-specific antibodies were detectable only thereafter. SBV genome was detected in all vaccinated animals and 3 out of 4 controls in serum samples taken after challenge infection. In conclusion, the investigated vaccine was not able to prevent an SBV-infection. Thus, vaccines for other related Simbu serogroup viruses can not substitute SBV-specific vaccines as an instrument for disease control.     

Detection of bovine virus diarrhea virus in a live bovine herpes virus 1 marker vaccine

In February 1999, 12 Dutch herds were vaccinated with a live bovine herpesvirus 1 vaccine from which bovine virus diarrhea virus (BVDV) could be isolated. All vaccine batches that were on the Dutch market and that had not yet reached the expiry date were tested for BVDV. In total, seven of 82 batches tested were found positive. Batch numbers TX3607, VB3914, VB3915, VB4046, TW3391, and TV3294 were positive for BVDV type 1, and batch number WG4622 was positive for BVDV type 2. This latter batch induced clinical signs of BVDV in an animal experiment with susceptible animals.     

Persistent bovine virus diarrhoea virus infection in a bull

Investigation of a sight defect in a pedigree bull, born as a result of artificial insemination and ovum transplantation, led to the finding that the animal was persistently infected with bovine virus diarrhoea virus. Virus was cultured from blood and from nasal and ocular swabs and was present in semen in high titre. At necropsy, virus was cultured from a wide range of tissues. The pathological findings are described and discussed as are the potential hazards of such infections.